Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 102-108

  Gonçalves, Anthony ^a   Viret, Frederic ^a   Ciccolini, Joseph ^b   Genre, Dominique ^a   Gravis, Gwenaelle ^a   Giovanini, Marc ^a,c   Camerlo, Jacques ^a   Catalin, Jacques ^b   Maraninchi, Dominique ^a,c   Viens, Patrice ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b School of Pharmacy   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEASIBILITY STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS; TIME FACTORS;

EID: 12244283075     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J., and Yang, C. P. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15: 55-61, 1993.
2. Ringel, I., and Horwitz, S. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl. Cancer Inst., 83: 288-291, 1991.
3. Cortes, J. E., and Pazdur R. Docetaxel. J. Clin. Oncol., 13: 2643-2655, 1995.
4. Figgitt, D. P., and Wiseman, L. R. Docetaxel: an update of its use in advanced breast cancer. Drugs, 59: 621-651, 2000.
5. Crown, J., and O'Leary, M. The taxanes: an update. Lancet, 355: 1176-1178, 2000.
6. Pazdur, R., Newman, R. A., Newman, B. M., Fuentes, A., Benvenuto, J., Bready, B., Moore, D., Jr., Jaiyesimi, I., Vreeland, F., Bayssas, M. M., et al. Phase I trial of Taxotere: five-day schedule. J. Natl. Cancer Inst., 84: 1781-1788, 1992.
7. Bissett, D., Setanoians, A., Cassidy, J., Graham, M. A., Chadwick, G. A., Wilson, P., Auzannet, V., Le Bail, N., Kaye, S. B., and Kerr, D. J. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res., 53: 523-527, 1993.
8. Extra, J-M., Rousseau, F., Bruno, R., Clavel, M., Le Bail, N., and Marty, M. Phase I and pharmacokinetic study of Taxotere (RP 65976; NSC 628503) given as a short intravenous infusion. Cancer Res., 53: 1037-1042, 1993.
9. Burris, H., Irvin, R., Kuhn, J., Kalter, S., Smith, L., Shaffer, D., Fields, S., Weiss, G., Eckardt, J., Rodriguez, G., et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol., 11: 950-958, 1993.
10. Tomiak, E., Piccart, M. J., Kerger, J., Lips, S., Awada, A., de Valeriola, D., Ravoet, C., Lossignol, D., Sculier, J. P., Auzannet, V., et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J. Clin. Oncol., 12: 1458-1467, 1994.
11. Piccart, M. J., and Di Leo, A. Future perspectives of docetaxel (Taxotere) in front-line therapy. Semin. Oncol., 24 (Suppl. 10): S10-27-S10-33, 1997.
12. Seibel, N. L., Blaney, S. M., O'Brien, M., Krailo, M., Hutchinson, R., Mosher, R. B., Balis, F. M., and Reaman, G. H. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin. Cancer Res., 5: 733-737, 1999.
13. Ajani, J. A., Welch, S. R., Raber, M. N., Fields, W. S., and Krakoff, I. H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investig., 8: 147-159, 1990.
14. Ciccolini, J., Catalin, J., Blachon, M. F., and Durand, A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J. Chromatogr. B Biomed. Sci. Appl., 759: 299-306, 2001.
15. 2 continuous infusion over 24 hr) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother. Pharmacol., 47: 45-50, 2001.
16. Zimmerman, G. C., Keeling, J. H., Burris, H. A., Cook, G., Irvin, R., Kuhn, J., McCollough, M. L., and Von Hoff, D. D. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch. Dermatol., 131: 202-206, 1995.
17. Bruno, R., Riva, A., Hille, D., Lebecq, A., and Thomas, L. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of Phase I and Phase II trials. Am. J. Health Syst. Pharm., 54 (Suppl. 2): S16-S19, 1997.
18. Rosing, H., Lustig, V., Koopman, F. P., ten Bokkel Huinink, W. W., and Beijnen, J. H. Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J. Chromatogr. B Biomed. Sci. Appl., 696: 89-98, 1997.
19. Rosing, H., Lustig, V., van Warmerdam, L. J., Huizing, M. T., ten Bokkel Huinink, W. W., Schellens, J. H., Rodenhuis, S., Bult, A., and Beijnen, J. H. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother. Pharmacol., 45: 213-218, 2000.
20. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.
21. McLeod, H. L., Kearns, C. M., Kuhn, J. G., and Bruno, R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother. Pharmacol., 42: 155-159, 1998.
22. Blagosklonny, M. V., and Fojo, T. Molecular effects of paclitaxel: myths and reality. Int. J. Cancer, 83: 151-156, 1999.
23. Jordan, M. A., and Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 10: 123-130, 1998.
24. Wang, L. G., Liu, X. M., Kreis, W., and Budman, D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol., 44: 355-361, 1999.
25. Wang, T. H., Wang, H. S., and Soong, Y. K. Paclitaxel -induced cell death: where the cell cycle and apoptosis come together. Cancer (Phila.), 88: 2619-2628, 2000.
26. André, N., Braguer, D., Brasseur, G., Gonçalves, A., Lemesle-Meunier, D., Guise, S., Jordan, M. A., and Briand, C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res., 60: 5349-5353, 2000.